American Thyroid Association
thyroid.org › home › patients portal › clinical thyroidology for the public › october 2016 › vol 9 issue 10 p.5-6
Increasing levothyroxine doses early in pregnancy is associated with a lower risk for pregnancy loss in hypothyroid women
October 9, 2016 - Many endocrinologists advise pregnant women to take a higher dose of Levothyroxine as soon as pregnancy is confirmed and to come in to have blood tests for TSH more often to ensure that the level remains normal.
Videos
PubMed Central
pmc.ncbi.nlm.nih.gov › articles › PMC9191263
Outcomes With Levothyroxine Treatment in Early Pregnancy With Subclinical Hypothyroidism - PMC
Healthy women with a singleton pregnancy were screened before 12 weeks of gestation for subclinical hypothyroidism using 2017 American Thyroid Association guidelines. They were treated with an initial dose of 50 mcg of levothyroxine and the dose was adjusted at six-week intervals to achieve a normal thyrotropin level.
PubMed Central
pmc.ncbi.nlm.nih.gov › articles › PMC4873573
Levothyroxine Dosage Requirement During Pregnancy in Well-Controlled Hypothyroid Women: A Longitudinal Study - PMC
It should be considered that some hypothyroid women are able to keep a normal serum TSH level in the first trimester of pregnancy and some of those who maintain a normal serum TSH concentration until the second trimester may still need to increment in levothyroxine dose during late gestation to maintain euthyroid status (Mandel, 2004). In summary, serum free T4 and TSH level should be measured within 1 month after start of treatment.
PubMed Central
pmc.ncbi.nlm.nih.gov › articles › PMC8900377
Levothyroxine dosages during pregnancy among hypothyroid women. An experience from a tertiary care center of Karachi, Pakistan, based on data from Maternal Hypothyroidism on Pregnancy Outcomes Study (MHPO-5) - PMC
Levothyroxine dosage of 280 hypothyroid women during pregnancy were reviewed. The median LT4 dosages prescribed before conception was 85.7 mcg per day which increased by 14.3 mcg per day in the first trimester (P 0.001). A significant difference in dosage was observed between controlled and uncontrolled TSH groups in the first trimester (P 0.05).
BioMed Central
bmcmedicine.biomedcentral.com › articles › 10.1186 › s12916-022-02586-9
Association of maternal levothyroxine use during pregnancy with offspring birth and neurodevelopmental outcomes: a population-based cohort study | BMC Medicine | Full Text
November 8, 2022 - 2). Gestational L-T4 users started L-T4 treatment at a median of 18 gestational weeks (Additional file 2: Table S3). Table 2 Comparison of children born from gestational L-T4 users with reference to children of euthyroid control mothers ... Propensity score weighted estimates from different comparison groups. A significantly increased risk of preterm birth was observed in children with maternal levothyroxine exposure during pregnancy when compared to mothers from the euthyroid control group (PS weighted OR: 1.22, 95% CI: 1.07, 1.39).
BMC Endocrine Disorders
bmcendocrdisord.biomedcentral.com › articles › 10.1186 › s12902-021-00699-5
Levothyroxine and the risk of adverse pregnancy outcomes in women with subclinical hypothyroidism: a systematic review and meta-analysis | BMC Endocrine Disorders | Full Text
February 27, 2021 - In the observational studies, there was moderate to serious risk of bias due to lack of adjustment for certain confounding variables, participant selection, and selective reporting of results. Pooled analyses showed decreased risk of pregnancy loss (RR: 0.79; 95% CI: 0.67 to 0.93) and neonatal death (RR: 0.35; 95% CI: 0.17 to 0.72) associated with levothyroxine treatment during pregnancy among women with SCH.
Bioscientifica
ec.bioscientifica.com › view › journals › ec › 13 › 3 › EC-23-0420.xml
Update on therapeutic use of levothyroxine for the management of hypothyroidism during pregnancy in: Endocrine Connections Volume 13 Issue 3 (2024)
March 1, 2024 - Real-world evidence suggests that hypothyroidism in pregnancy is often overlooked or that LT4 is not given appropriately to gain tight control of TSH. More research is needed to identify the barriers to optimal thyroid care with LT4 at this crucial time. Keywords: levothyroxine; hypothyroidism; pregnancy; miscarriage
American Thyroid Association
thyroid.org › home › thyroid health – management of hypothyroidism during pregnancy: when and how to treat?
Thyroid Health Blog - Management of Hypothyroidism During Pregnancy: When and how to treat?
March 3, 2024 - The patient may be advised to increase the dose of levothyroxine by 20 to 30 % as soon as pregnancy is confirmed to avoid any inadvertent delay. One way to achieve this easily is by increasing the dose by two extra daily doses a week. Continuation of or starting the use of desiccated thyroid or triiodothyronine(T3) preparations is not currently recommended during pregnancy.
SingleCare
singlecare.com › home › can you take levothyroxine during pregnancy?
Is levothyroxine safe during pregnancy?
January 21, 2025 - Your body typically has a higher demand for thyroid hormones during pregnancy, says Dr. Baldwin. This demand can increase as your pregnancy progresses. That means your pre-pregnancy dose (or starting dose if you’re diagnosed during pregnancy) of levothyroxine may need to increase for the nine months you’re expecting.
NCBI
ncbi.nlm.nih.gov › books › NBK585637
Levothyroxine in Pregnancy - 70 Years of Levothyroxine - NCBI Bookshelf
March 12, 2021 - Thyroid hormone homeostasis changes markedly during pregnancy, and first trimester-specific reference ranges for thyrotropin (thyroid-stimulating hormone, TSH) are needed to diagnose hypothyroidism. Treatment consists in levothyroxine (LT4) in this setting (triiodothyronine or desiccated thyroid preparations have no role here).
Healio
healio.com › news › endocrinology › 20201209 › levothyroxine-overtreatment-during-pregnancy-increases-odds-for-preterm-delivery
Levothyroxine overtreatment during pregnancy increases odds for preterm delivery
December 9, 2020 - Compared with preconception levothyroxine dosage, the median increases were 17.9% at first trimester, 35.7% at second trimester and 43.6% at third trimester. Of the 8,774 women who had TSH testing during pregnancy, 4% were in the levothyroxine overtreatment group and 9.1% were in the undertreatment group.